Conditions: Parkinson's Disease
Keywords: Rasagiline Azilect Parkinson´s Disease Motor fluctuations
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 321
Healthy volunteers: no

Brief summary:
The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in levodopa-treated Parkinson's Disease (PD) Chinese patients with motor fluctuations. Azilect® (Rasagiline) is indicated for the treatment of idiopathic PD as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Placebo intervention 2: Azilect®
Intervention descriptions: intervention 1: Once daily; tablet; orally; 16 weeks intervention 2: 1 mg daily; tablet; orally; 16 weeks

Protocol document: